SMARCB1 and neoplasm: Later, mutations and aberrant expression of SMARCB1 have been reported in various tumor types including familial schwannomas (Hulsebos et al, 2007), melanomas (Stockman et al, 2015), and rhabdoid tumors from different locations (Eaton et al, 2011).